Summary

Aarti Drugs Limited, a Mumbai based diversified and fully integrated pharmaceutical company, announced its Unaudited Financial Results for the quarter ending 30th June 2025. The company reported a 6% YoY growth in revenue, a 12% YoY growth in EBITDA, and a 62% YoY increase in PAT. The formulation segment saw a 14% YoY growth in revenue.

Key Highlights

1. 1

   Revenue for Q1 FY26 stood at Rs. 590.8 crores as against Rs. 556.5 crores in Q1 FY25, a growth of 6% YoY

2. 2

   EBITDA stood at Rs. 74.4 crores as against Rs. 66.1 crores in Q1 FY25, a growth of 12% YoY

3. 3

   PAT stood at Rs. 54.0 crores as against Rs. 33.3 crores in Q1 FY25, an increase of 62% YoY

4. 4

   Formulation revenue stood at Rs. 80.3 crores as against Rs. 70.5 crores in Q1 FY25, up 14% YoY

5. 5

   The company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

6. 6

   The new greenfield manufacturing facility in Sayakha, Gujarat has started trial productions

7. 7

   The new greenfield Salicylic Acid plant at Tarapur is progressing well and is expected to begin contributing to the Company’s financials from the third quarter onwards

8. 8

   Aarti Drugs is strategically positioned to meet the demand shift for APIs due to high tariffs on pharmaceutical products and APIs imported from countries like China